BACKGROUND

Mechanism of action: eftilagimod alpha (soluble LAG-3 protein) (LAG-3 domains fused to human IgG1) activates antigen-presenting cells (APCs) leading to a broader immune response against cancer, including increases in activated T cells (CDA0219) (Figure 1).

Predictive value of the anti-LAG-3 mAb: efti is an MHC-Class II antagonist and not a LAG-3 antagonist.

Safety

- No treatment-related deaths occurred (Table 2).

Table 2. Overall response, ITT (N=37)

| Response | RECIST 1.1 | RECIST 1.1 # | L1 CPS [0-4] | RECIST 1.1 #
|----------|------------|-------------|--------------|-------------
| n (%)    | 8 (21.6)   | 6 (16.2)    | 17 (46.9)    | 9 (24.3)    |
| CR       | 0          | 0           | 0            | 0           |
| PR       | 8 (21.6)   | 6 (16.2)    | 17 (46.9)    | 9 (24.3)    |
| SD       | 17 (46.9)  | 12 (32.4)   | 6 (16.2)     | 6 (16.2)    |
| PD       | 12 (32.4)  | 13 (35.1)   | 2 (5.1)      | 11 (29.7)   |

Stable Disease

Stable Disease

- efti in combination with pembrolizumab is safe, showing no new safety signals.

- Encouraging ORR (RECIST) of 29.7% (95% CI: 15.9–47.0) in 2nd line HNSCC pts responding to combination therapy of efti + pembrolizumab.

- Early onset of responses (median ~2 mo) that were deep (13.5% CRs) and

- No new safety signals.

- Encouraging ORR (RECIST) of 29.7% (95% CI: 15.9–47.0) in 2nd line HNSCC pts responding to combination therapy of efti + pembrolizumab.

- Early onset of responses (median ~2 mo) that were deep (13.5% CRs) and

- No new safety signals.

- Encouraging ORR (RECIST) of 29.7% (95% CI: 15.9–47.0) in 2nd line HNSCC pts responding to combination therapy of efti + pembrolizumab.

- Early onset of responses (median ~2 mo) that were deep (13.5% CRs) and